The decisions that slow down or fragilize pharma R&D.
Decivio covers program, trial and portfolio decisions. Teams typically start where the capital is largest and the uncertainty highest.
Phase II → Phase III readiness
When scientific promise, unresolved uncertainty and major capital exposure must become one defensible progression decision.
Endpoint strategy
When clinical relevance, feasibility, regulatory expectations and differentiation point in different directions.
Recruitment rescue
When enrollment drift starts threatening cost, timelines and readout—but the right intervention is still unclear.
Protocol redesign / amendment
When emerging signals challenge the protocol and waiting can be as consequential as changing course.
Competitive response
When the science still holds, but a faster or better-differentiated competitor changes the program's strategic value.
Safety re-review
When benefit-risk uncertainty creates unease and the conditions for continuing need to become explicit.
Portfolio reprioritization
When limited resources force choices across programs that were never designed to be compared.
Which decision is coming up for your team?
The pilot is designed around one real critical decision, the best way to see what a decision layer changes.